Evidence map›Paper›PMID 34535740›Full record

ArticleScientific reports2021

Prolyl isomerase Pin1 plays an essential role in SARS-CoV-2 proliferation, indicating its possibility as a novel therapeutic target.

Takeshi Yamamotoya, Yusuke Nakatsu, Machi Kanna, Shun Hasei, Yukino Ohata, Jeffrey Encinas, Hisanaka Ito, Takayoshi Okabe, Tomoichiro Asano, Takemasa Sakaguchi

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Duration of infectious viral shedding in patients with mild to moderate COVID-19 treated with REGN-CoV2.Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy · 2022
    Article
  7. Article
  8. Article
  9. Roles of peptidyl prolyl isomerase Pin1 in viral propagation.Frontiers in cell and developmental biology · 2022
    Review
  10. Review
  11. Article
  12. Review
  13. Frontiers in pharmacology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Takeshi Yamamotoya *Department of Medical Chemistry, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.
Yusuke Nakatsu *Department of Medical Chemistry, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.
Machi KannaDepartment of Medical Chemistry, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.
Shun HaseiDepartment of Medical Chemistry, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.
Yukino OhataDepartment of Medical Chemistry, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.
Jeffrey EncinasAnenti Therapeutics Japan, Inc., 4-3 Yamaashiya-cho, Ashiya, 659-0082, Japan.
Hisanaka ItoSchool of Life Sciences, Tokyo University of Pharmacy and Life Sciences, 1432-1 Horinouchi, Hachioji, Tokyo, 192-0392, Japan.
Takayoshi OkabeDrug Discovery Initiative, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan.
Tomoichiro AsanoDepartment of Medical Chemistry, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan. tasano@hiroshima-u.ac.jp.
Takemasa SakaguchiDepartment of Virology, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan. tsaka@hiroshima-u.ac.jp.
Hiroshima University · JPThe University of Tokyo · JPTokyo University of Pharmacy and Life Sciences · JP

Funding

Hiroshima Prefecture, Japan Goverment-Academia CollaborationJapan Agency for Medical Research and Development Development of Technology to Control Viral InfectionsJapan Society for the Promotion of Science Grant-in-Aid for Scientific Research (B)Japan Society for the Promotion of Science Grant-in-Aid for Scientific Research (C)
6 · The paper itself

Abstract

Novel coronavirus disease 2019 (COVID-19) has emerged as a global pandemic with far-reaching societal impact. Here we demonstrate that Pin1 is a key cellular molecule necessary for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) propagation. In this study, siRNA-mediated silencing of Pin1 expression markedly suppressed the proliferation of SARS-CoV-2 in VeroE6/TMPRSS2 cells. In addition, several recently generated Pin1 inhibitors showed strong inhibitory effects on SARS-CoV-2 proliferation, measured by both viral mRNA and protein synthesis, and alleviated the cytopathic effect (CPE) on VeroE6/TMPRSS2 cells. One compound, termed H-77, was found to block SARS-CoV-2 proliferation at an EC

Indexed as

AnimalsChlorocebus aethiopsCOVID-19NIMA-Interacting Peptidylprolyl IsomerasePandemicsSARS-CoV-2Vero CellsVirus InternalizationVirus ReplicationNIMA-Interacting Peptidylprolyl Isomerase

Identifiers

PMID34535740
PMCPMC8448864
OpenAlexW3137805250

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.